INTRODUCTION
============

There are innumerable studies supporting the principle of "the lower, the better" for cardiovascular (CV) risk factors in terms of outcomes. Multiple cholesterol management sources have suggested lowering low-density lipoprotein cholesterol (LDL-C) levels to the greatest extent possible to prevent cardiovascular disease (CVD) in high-risk groups in accordance with recent CV outcome trials that showed additional benefits for CVD prevention from using proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to lower mean LDL-C levels to 30 mg/dL \[[@b1-enm-2020-35-2-217]--[@b3-enm-2020-35-2-217]\]. In addition, debate continues regarding lower blood pressure (BP) control targets based on the Systolic Blood Pressure Intervention Trial (SPRINT) results \[[@b4-enm-2020-35-2-217],[@b5-enm-2020-35-2-217]\]. In patients with diabetes, although concerns remain regarding the deleterious effects of hypoglycemia on CV outcomes and cognitive dysfunction, strict glycemic control with a glycated hemoglobin (HbA1c) level \<6.5% or 7.0% is optimally recommended, dependent on different associations \[[@b6-enm-2020-35-2-217],[@b7-enm-2020-35-2-217]\].

Studies on the effects of BP variability on health outcomes have been conducted for almost a decade \[[@b8-enm-2020-35-2-217]\]. However, the impacts of body weight variability and the effects of starvation and body weight regain on health outcomes were first measured in starvation victims of World War II, in the so-called Minnesota Experiment \[[@b9-enm-2020-35-2-217]\]. The effects of glucose variability on health outcomes began to be more thoroughly and precisely evaluated after continuous glucose monitoring (CGM) systems and antidiabetic medications targeting postprandial glucose, such as dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists, became available \[[@b10-enm-2020-35-2-217],[@b11-enm-2020-35-2-217]\]. Studies on lipid variability were presumably initiated due to the lipid variability seen in large statin trials, and the issue of whether statin adherence affects CV outcomes \[[@b12-enm-2020-35-2-217],[@b13-enm-2020-35-2-217]\]. In summary, most variability in CV risk factors is linked to medication adherence, the stability of the medication's effect, and the degree of lifestyle modifications.

In this study, we review the current knowledge regarding the effects of variability in CV risk factors on mortality and metabolic and CV health outcomes and discuss possible mechanisms.

BODY WEIGHT VARIABILITY
=======================

Dieting has multiple meanings, including "intentional weight loss" or "a specific eating pattern." Although obesity is considered a deleterious health problem worldwide, many problems are caused by weight control measures that are too strict and the perceived need for excessive leanness. Many people with normal weight want to lose weight, and they repeat the cycle of losing and gaining weight multiple times throughout their lives. This is known as weight cycling. Recent studies have reported that although being obese has a negative impact on health, weight cycling is also dangerous for cardiometabolic health \[[@b14-enm-2020-35-2-217]\].

Although the exact mechanisms underlying the effects of weight cycling on health outcomes are not clear, two hypotheses address this phenomenon: the "repeated overshoot" and "increased visceral energy repartitioning" hypotheses \[[@b14-enm-2020-35-2-217],[@b15-enm-2020-35-2-217]\]. Weight cycling could cause enhanced weight gain during the calorie-excess period of weight fluctuation. Sustained fluctuations in energy balance during weight cycling can lead to potential fluctuations in CV risk factors, which may increase above normal values during periods of weight regain. Therefore, fluctuations in risk factors impose an extra load on the heart and may lead to vascular injury ([Fig. 1](#f1-enm-2020-35-2-217){ref-type="fig"}) \[[@b15-enm-2020-35-2-217]\]. Another plausible mechanism is repartitioning of fat and lean mass after weight cycling \[[@b16-enm-2020-35-2-217]\]. Weight cycling causes increased abdominal obesity and weight loss-associated adaptations in resting energy expenditure \[[@b17-enm-2020-35-2-217]\]. In addition, reconstitution of skeletal muscle in the trunk during spontaneous 6-month weight regain lags behind that seen in the extremities, resulting in a preferential regain of lean mass in the limbs compared with the trunk in weight-regaining subjects \[[@b18-enm-2020-35-2-217]\].

The effects of weight fluctuation on mortality are controversial. In a study of 3,278 participants aged 65 years or older at baseline in United States communities in the Cardiovascular Health Study, weight cycling was associated with a significant increase in mortality \[[@b19-enm-2020-35-2-217]\]. In another study of 4,796 Japanese atomic bomb survivors who were followed up for 27 years, variation in body weight was associated with a 1.25-fold increase in all-cause mortality, and this association was independent of body mass index category \[[@b20-enm-2020-35-2-217]\]. In a recent meta-analysis of 15 studies, the pooled overall hazard ratio (HR) for all-cause mortality in the groups with the greatest weight fluctuation compared with those with most stable weight was 1.45 \[[@b21-enm-2020-35-2-217]\]. In contrast, in a study analyzing 55,983 men and 66,655 women in the Cancer Prevention Study II Nutrition Cohort, weight cycling was not associated with a significant increase in mortality \[[@b22-enm-2020-35-2-217]\]. The considerable heterogeneity among the studies explains the discrepancies between the results regarding the effects of weight fluctuation on mortality. In addition, results regarding the effects of weight on mortality must be interpreted with caution, since weight fluctuation could be caused by the presence of untreated life-threatening diseases.

Controversy also exists regarding the effects of weight fluctuation on diabetes risk. In a 6-year follow-up study in 46,634 participants from the Nurses' Health Study II, the association between weight cycling and higher rates of type 2 diabetes was no longer significant after adjustment for overall weight status \[[@b23-enm-2020-35-2-217]\]. In addition, in a Japanese study that analyzed weight changes over 10 years, participants who showed sustained weight gain had a 3-fold higher risk for diabetes than those whose weight remained stable \[[@b24-enm-2020-35-2-217]\]. However, individuals whose weight fluctuated had a lower diabetes risk than the individuals whose weight was stable. In contrast, in a study analyzing 53,088 participants of the European Prospective Investigation into Cancer and Nutrition (EPIC)-Germany cohort, in which weight cycling was defined by an annual weight change of 1.125 kg per year of higher, weight cycling was associated with a 1.4-fold increased risk for diabetes than stable weight \[[@b25-enm-2020-35-2-217]\]. In another study of 4,818 Korean health screening program participants, who were followed up for 5 years, the group with the largest annual weight change showed a 1.78-fold higher risk for diabetes than those who had the smallest weight change \[[@b26-enm-2020-35-2-217]\]. Individuals who were overweight or obese and had high fluctuations showed a 2.7-fold higher risk for diabetes compared with those who were lean and had low fluctuations in body weight. The result of another long-term study with a 16-year follow-up suggests that the effect of body weight fluctuation on incident diabetes depends on the presence of obesity at baseline \[[@b27-enm-2020-35-2-217]\]. To summarize, there is no clear consensus regarding the effect of weight fluctuation on the risk of diabetes mellitus because of the large discrepancies among the results of various studies performed with various study populations.

Weight fluctuation also affects the risk for CVD. An analysis of the Framingham Heart Study 32-year follow-up data showed that participants with highly variable body weight showed a significantly higher risk for mortality and coronary heart disease \[[@b28-enm-2020-35-2-217]\]. In a recent study of 9,509 participants in the Treating to New Target (TNT) trial, body weight fluctuation was significantly associated with higher mortality and a higher rate of CV events, independent of traditional CV risk factors, supporting previous results regarding the deleterious effects of weight fluctuation on CV event development \[[@b29-enm-2020-35-2-217]\].

Finally, weight fluctuation could have an influence on cancer risk. In 80,943 postmenopausal women in the Women's Health Initiative, the participants who answered that they had experienced weight cycling more than once in their life showed a higher risk for breast cancer and endometrial cancer than those who answered that they had a stable weight \[[@b30-enm-2020-35-2-217]\]. In contrast, in the Cancer Prevention Study II, postmenopausal women who experienced weight cycling did not show a significantly increased risk for endometrial cancer \[[@b31-enm-2020-35-2-217]\]. Other risk factors and surrogate markers are affected by body weight fluctuation, but they are not reviewed here ([Fig. 2](#f2-enm-2020-35-2-217){ref-type="fig"}). More studies are needed to draw firmer conclusions.

In conclusion, weight fluctuation influences the risk of diabetes, CVD, mortality, and cancer, as observed in previous studies. However, the results are inconsistent because of differences in study populations and methods used for assessing weight cycling. The absence of a consensus on a standard definition of weight cycling or fluctuation may be the largest challenge for future studies in this field.

LIPID VARIABILITY
=================

The benefits of lipid-lowering therapy, mainly with the use of statins, for the primary and secondary prevention of CVD have been well established by major clinical trials \[[@b32-enm-2020-35-2-217]\]. However, several studies have shown that discontinuation of statins increases short-term or long-term mortality and vascular events in patients with CVD \[[@b33-enm-2020-35-2-217]--[@b35-enm-2020-35-2-217]\]. Event rates and the risk of worse outcomes were even higher in patients who discontinued statins than in those who were not using statins. Because the rebound phenomenon induced by withdrawal of statins abrogates their beneficial effects on inflammation, endothelial dysfunction, hemostasis, and blood rheology in a relatively short-term period \[[@b36-enm-2020-35-2-217],[@b37-enm-2020-35-2-217]\], it is conceivable that unstable lipid levels might have detrimental effects.

Studies examining intra-individual day-to-day or seasonal variability in serum lipid parameters have shown that biological variability in cholesterol levels exists \[[@b38-enm-2020-35-2-217],[@b39-enm-2020-35-2-217]\]. However, the clinical implications of short-term lipid variability are unknown. The clinical significance of lipid variability has emerged as a topic of interest only recently, mainly in terms of long-term (visit-to-visit) variability. The first study suggesting that total cholesterol (TC) variability should be regarded as a risk factor for mortality and CV diseases was reported in 1994 \[[@b40-enm-2020-35-2-217]\]. Using the Framingham Heart Study cohort, TC variability calculated from six biennial measurements was shown to be associated with all-cause mortality in men and with CVD in both sexes over a 24-year follow-up period. A *post hoc* analysis from the TNT trial, which enrolled patients with stable coronary artery disease, demonstrated that LDL-C variability predicted CV outcomes, independent of mean LDL-C levels \[[@b12-enm-2020-35-2-217]\]. A one standard deviation (SD) increase in LDL-C variability was associated with a significant increase of any coronary event by 16%, any CV event by 11%, death by 23%, myocardial infarction (MI) by 10%, and stroke by 17%. Subsequent reports reproduced this finding in patients who had ST-elevation MI or underwent percutaneous coronary intervention, highlighting the role of LDL-C and high-density lipoprotein cholesterol (HDL-C) variability as an independent predictor of secondary adverse events \[[@b41-enm-2020-35-2-217], [@b42-enm-2020-35-2-217]\]. A similar phenomenon was observed in the general population without CVD. In a nationwide cohort study using a Korean claims database, the multivariable-adjusted HRs and 95% confidence intervals (CIs) comparing the highest and lowest quartiles of TC variability were 1.26 (95% CI, 1.24 to 1.28) for all-cause mortality, 1.08 (95% CI, 1.05 to 1.11) for MI, and 1.11 (95% CI, 1.08 to 1.14) for stroke \[[@b43-enm-2020-35-2-217]\]. Similarly, both low HDL-C mean levels and high HDL-C variability were associated with a higher risk for MI, stroke, and mortality, which had additive effects \[[@b44-enm-2020-35-2-217]\]. These associations were more prominent in people who were not taking lipid-lowering agents, suggesting that mechanisms other than medication nonadherence may explain this relationship.

More recent studies have expanded the analysis of lipid variability to include other health outcomes. Large variations in TC and HDL-C were found to be associated with a higher risk of developing diabetes \[[@b45-enm-2020-35-2-217],[@b46-enm-2020-35-2-217]\] or end-stage renal disease \[[@b47-enm-2020-35-2-217],[@b48-enm-2020-35-2-217]\]. In addition, greater LDL-C variability was associated with an increased progression to dialysis in patients with stage 3 chronic kidney disease \[[@b49-enm-2020-35-2-217]\], and triglyceride variability was linked to incident microalbuminuria in patients with type 2 diabetes \[[@b50-enm-2020-35-2-217]\]. High lipid variability was associated with a higher risk of developing atrial fibrillation \[[@b51-enm-2020-35-2-217],[@b52-enm-2020-35-2-217]\]. Analysis from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) study using neuroimaging and cognitive function tests demonstrated that higher visit-to-visit LDL-C variability was associated with lower cognitive performance, lower cerebral blood flow, and greater white matter hyperintensity load, independent of mean LDL-C levels and statin treatment \[[@b53-enm-2020-35-2-217]\]. Lee et al. \[[@b54-enm-2020-35-2-217]\] also reported that high TC variability predicted all-cause dementia, Alzheimer disease, and vascular dementia in the general population without metabolic diseases.

Despite ample evidence provided by epidemiological studies, the pathophysiological mechanisms by which lipid variability leads to adverse health outcomes are still largely unknown. High cholesterol variability may induce fluctuations in the composition of vascular plaques, making them more atheromatous and vulnerable to rupture. A *post hoc* analysis of nine clinical trials including 4,976 patients with coronary artery disease who underwent serial intravascular ultrasonography found that greater visit-to-visit variability in LDL-C, non-HDL-C, the TC/HDL-C ratio, and apolipoprotein B was significantly associated with coronary atheroma progression \[[@b55-enm-2020-35-2-217]\]. Endothelial dysfunction, oxidative stress, and inflammatory processes may act as mediators, as these are key pathophysiological components of many diseases induced by metabolic dysfunction. However, direct evidence is lacking and further investigation is warranted.

Polymorphisms in apolipoprotein genes have also been suggested as possible contributors to intra-individual lipid variability \[[@b56-enm-2020-35-2-217],[@b57-enm-2020-35-2-217]\]. In a genome-wide association study, most genetic variants were not associated with lipid variability, although two suggestive signals for LDL-C variability (KIAA0391 and amiloride-sensitive cation channel 1 neuronal) and one for HDL-C variability (Dickkopf WNT signaling pathway inhibitor 3) were detected \[[@b58-enm-2020-35-2-217]\].

Finally, high variability in biological parameters may reflect general frailty and could be a marker of increased risk, rather than a true risk factor. However, the strong and consistent results found across many different studies support a possible causal relationship between lipid variability and adverse health outcomes.

The issue of translating these findings to clinical practice should be addressed by further investigations. Presumably, maintaining stable lifestyle patterns, including diet, exercise, and body weight, is important. It is unclear whether statin treatment or dosing affects lipid variability. In the PROSPER study, the pravastatin treatment group had higher LDL-C and HDL-C variability than the placebo group \[[@b58-enm-2020-35-2-217]\]. However, in the TNT trial, an atorvastatin dose of 80 mg/day was associated with significantly lower LDL-C variability than an atorvastatin dose of 10 mg/day dose \[[@b12-enm-2020-35-2-217]\]. It is worthwhile to investigate whether lipid variability induced by a monthly high-dosing schedule of PCSK9 inhibitor would cause any adverse effects \[[@b59-enm-2020-35-2-217],[@b60-enm-2020-35-2-217]\].

BLOOD PRESSURE VARIABILITY
==========================

BP is characterized by marked short-term fluctuations occurring within a 24-hour period, including beat-to-beat, hour-to-hour, and day-to-night changes. Long-term, substantial variations in BP have been shown to occur over more prolonged periods of time, for example days (day-to-day), weeks, months (visit-to-visit), seasons, and even years \[[@b61-enm-2020-35-2-217]\]. Previous studies on the prognostic relevance of BP variability have focused on short-term BP variability assessed by 24-hour ambulatory BP monitoring \[[@b61-enm-2020-35-2-217]\]. However, evidence suggests that high day-to-day or visit-to-visit BP variability is associated with increased prevalence and severity of cardiac, vascular, and renal damage and an increased risk of fatal and nonfatal CV events \[[@b62-enm-2020-35-2-217]--[@b64-enm-2020-35-2-217]\]. In clinical trials, long-term BP variability is associated with CV outcomes to a far greater extent than short-term BP variability \[[@b61-enm-2020-35-2-217]\]. Long-term BP variability has been shown to be reproducible; therefore, it is not a random phenomenon \[[@b61-enm-2020-35-2-217]\].

Some potential mechanisms underlying long-term BP variability, particularly increased arterial stiffness, have been postulated in previous studies \[[@b65-enm-2020-35-2-217]\]. Factors influencing the degree of BP control, such as compliance with the prescribed therapeutic regimen and correct dosing and titration of antihypertensive treatment, or errors in BP measurement, can influence visit-to-visit BP variability. High variability in BP is a marker of the percentage of time that BP is not within the target range, which can contribute to a higher incidence of stroke and other CV outcomes. Among patients with hypertension, poor drug compliance is one of the most common factors affecting visit-to-visit BP variability. Visit-to-visit BP variability might be differentially affected by various classes of antihypertensive drugs \[[@b66-enm-2020-35-2-217],[@b67-enm-2020-35-2-217]\]. A regimen based on the calcium-channel blocker amlodipine was found to be associated with lower intraindividual BP variability and a lower incidence of stroke than a regimen based on the beta-blocker atenolol, independent of mean BP \[[@b66-enm-2020-35-2-217],[@b67-enm-2020-35-2-217]\]. The protective effect of antihypertensive treatment depends not only on the magnitude of mean BP reduction, but also on the consistency of on-treatment BP control.

However, BP variability has also been reported to be associated with the risk of CVD in individuals without hypertension \[[@b68-enm-2020-35-2-217],[@b69-enm-2020-35-2-217]\]. BP variability is also thought to be determined by mechanisms other than drug effects or adherence. For example, higher variability in multiple biological parameters might be observed in patients with systemic conditions and generalized frailty \[[@b68-enm-2020-35-2-217]\]. Therefore, it is possible that high BP variability is an epiphenomenon of other systemic conditions that increase CV or mortality risk. Visit-to-visit variability of systolic BP exceeding 10 to 12 mm Hg or diastolic BP variability exceeding 8 mm Hg significantly increased the risk of hospitalization and all-cause mortality \[[@b70-enm-2020-35-2-217]\]. A study by Bae et al. \[[@b71-enm-2020-35-2-217]\] followed up a total of 8,199,089 healthy subjects for 7.9 years and showed that increased visit-to-visit BP variability was an independent risk factor for the development of end-stage renal disease.

High BP variability enhances periodic pressure loading and shear stress on the CV system and the progression of atherosclerosis \[[@b61-enm-2020-35-2-217]\]. Multiple adverse pathological processes including cardiac diastolic dysfunction, endothelial dysfunction, increased intima-media thickness, and arterial stiffness have been proposed as potential mechanisms to explain the association between visit-to-visit BP variability and CV outcomes \[[@b72-enm-2020-35-2-217]\]. In the setting of increased BP variability, increased sympathetic nerve activity plays an important role in the progression of hypertension and kidney disease. In addition, chronic sympathetic nerve hyperactivity can damage renal blood vessels by inducing smooth muscle and fibroblast proliferation in the vessel wall, reduce nitric oxide bioavailability resulting in intrarenal vasoconstriction, decrease blood flow, and worsen renal injury \[[@b71-enm-2020-35-2-217]\].

GLUCOSE VARIABILITY
===================

Despite the lack of consensus regarding the most appropriate definition and tools for its assessment, glucose variability is involved in the pathogenesis of the vascular complications of diabetes \[[@b73-enm-2020-35-2-217]\]. There is no consensus on the gold standard for measuring glucose variability in clinical practice \[[@b73-enm-2020-35-2-217]\]. Two different methods of measuring intra-day glucose variability have been described in the literature: self-monitoring of blood glucose and CGM \[[@b74-enm-2020-35-2-217]\]. This is similar to the two methods of measuring BP variability (home BP monitoring and 24-hour ambulatory BP monitoring). Visit-to-visit fasting blood glucose (FBG) variability or visit-to-visit HbA1c variability could be used as an indicator of long-term glucose variability.

In type 1 diabetes, short-term glucose variability, measured by the coefficient of variation, showed greater explanatory power for hypoglycemia than the mean glucose level when the glucose threshold was set at 54 mg/dL \[[@b75-enm-2020-35-2-217]\]. According to the International Consensus on Use of CGM, stable glucose levels are defined as a coefficient of variation \<36% and unstable glucose levels are defined as a coefficient of variation ≥36% \[[@b76-enm-2020-35-2-217]\]. For example, a person with a mean glucose of 150 mg/dL and a SD of 60 mg/dL would have a coefficient of variation of 40%; this person would be categorized as having unstable glucose levels. High glucose variability is an independent risk factor for severe hypoglycemia and subsequent hospitalization in patients with diabetes \[[@b77-enm-2020-35-2-217]\]. The incidence and duration of hypoglycemia are associated with glucose variability \[[@b74-enm-2020-35-2-217]\]. In fact, hypoglycemia is associated with both macrovascular and microvascular complications in patients with type 2 diabetes mellitus \[[@b78-enm-2020-35-2-217]\]. Patients with type 1 diabetes are especially vulnerable to glucose variability. In type 1 diabetes, even when HbA1c levels are within the target range, there is a 2.92-fold increased risk of CV mortality \[[@b79-enm-2020-35-2-217]\].

Visit-to-visit variability in FBG and HbA1c was associated with the risks of microvascular and macrovascular events and all-cause mortality among patients with type 2 diabetes using data from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial \[[@b80-enm-2020-35-2-217]\]. Variability in FBG over the course of \>7.5 years of follow-up was a potent predictor of ischemic stroke in 28,534 patients with type 2 diabetes in the Taiwan Diabetes Study \[[@b81-enm-2020-35-2-217]\]. Consistency in glycemic control is important in reducing the risks of vascular events and death in type 2 diabetes.

Few previous studies have investigated the prognostic significance of glucose variability in individuals without diabetes. Recently, visit-to-visit fasting glucose variability has been reported as a risk factor for the development of type 2 diabetes \[[@b80-enm-2020-35-2-217]\]. We recently showed that high variability of FBG was an independent predictor of mortality and CV events among the general population \[[@b68-enm-2020-35-2-217]\]. For the highest quartile in FBG variability compared with the lowest quartile, the risk of all-cause mortality was 20% higher (HR, 1.20; 95% CI, 1.18 to 1.23), MI by 16% (HR, 1.16; 95% CI, 1.12 to 1.21), and that of stroke was 13% higher (HR, 1.13; 95% CI, 1.09 to 1.17). High glucose variability was associated with longer hospitalization and increased mortality in hospitalized patients, regardless of the presence of diabetes \[[@b81-enm-2020-35-2-217]\].

Although the exact mechanism remains to be elucidated, several mechanisms could be involved in the associations between visit-to-visit glycemic variability and various outcomes. Glucose fluctuation has been shown to cause overproduction of oxidative stress, an increase in inflammatory cytokines, and a loss of pancreatic beta-cells due to increased apoptotic cell death \[[@b74-enm-2020-35-2-217]\].

CONCLUSIONS
===========

In this review, we examined the current literature regarding variability in four CV risk factors: body weight, lipid profiles, BP, and blood glucose. In summary, variability in most of these risk factors has generally been found to be associated with increased all-cause mortality and risk of CVD, although some discrepancies in the results exist ([Fig. 2](#f2-enm-2020-35-2-217){ref-type="fig"}). In addition, through unknown mechanisms, fluctuations in these risk factors contribute to diabetes and obesity, even at a lower stage. Another factor that should be considered is that some of the fluctuation in risk factors is affected by adherence with the treatment regimen or the degree of lifestyle modification \[[@b82-enm-2020-35-2-217]\]. Most of the mechanisms suggested are based on very few consistent results, warranting further studies that might provide more definitive conclusions regarding the direct associations of variability in the abovementioned CV risk factors with health outcomes.
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![High variability in body weight, lipid profile, blood pressure, and blood glucose is associated with increased risks of all-cause mortality, cardiovascular diseases, and other health outcomes.](enm-2020-35-2-217f2){#f2-enm-2020-35-2-217}
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